Real-time enrollment status for this relapsed/refractory acute myeloid leukemia (aml) clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 6:41 AM UTC
| NCT Number | NCT05143996 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Acute Myeloid Leukemia (AML) |
| Phase | Clinical Trial |
| Target Enrollment | 60 participants |
| Active Locations | 11 sites in the US |
| Sponsor | Cullinan Therapeutics Inc. |
| Last Updated on CT.gov | January 16, 2026 (Jan 16, 2026) |
As of July 13, 2026: Clinical trial NCT05143996 is currently recruiting participants. This clinical trial study for relapsed/refractory acute myeloid leukemia (aml) is actively seeking new participants at 11 locations across the United States. The study is sponsored by Cullinan Therapeutics Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05143996 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 11 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05143996 was last updated Jan 16, 2026 (January 16, 2026). HelloStudys verifies this status automatically.